Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.36 |
| ▸ | PREP | P48147 | 2/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4953959 | 1.00 | CYP1A2 (0.37) | CYP1A2ATMCTSSCTSKCTSB | |
| SCHEMBL14277715 | 0.89 | ATM (0.38) | CYP1A2ATMCTSSCTSKCTSB | |
| SCHEMBL3960378 | 0.83 | ATM (0.42) | ATMCTSSCTSKCASP1ELANE | |
| SCHEMBL3962685 | 0.83 | ATM (0.42) | ATMCTSSCTSKCASP1ELANE | |
| SCHEMBL4950100 | 0.78 | ATM (0.39) | CYP1A2ATMCTSSCTSKCAPN1 | |
| SCHEMBL4950109 | 0.78 | ATM (0.39) | CYP1A2ATMCTSSCTSKCAPN1 | |
| SCHEMBL4951270 | 0.78 | ATM (0.39) | CYP1A2ATMCTSSCTSKCAPN1 | |
| SCHEMBL4951359 | 0.76 | ATM (0.42) | CYP1A2ATMCTSSCTSKCTSB | |
| SCHEMBL14290447 | 0.76 | HTR2A (0.34) | — | |
| SCHEMBL4952732 | 0.74 | ATM (0.39) | ATMCTSSCTSKELANECTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425572-B2 | Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma | ALCON, INC. (CH) | 2008-09-16 | — | — | US | disclosed |
| WO-2006062839-A1 | USE OF DIOXINDOINDAZOLES AND DIOXOLOINDAZOLES FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2006-06-15 | — | — | WO | disclosed |
| US-20060122251-A1 | Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma | ALCON, INC. | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122251-A1 | Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma | CYP11B2, CYP11B1, PDE3A | CYP1A2 157/4885ATM 3304/4885CTSS 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.